Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.44 |
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2915731 | 0.98 | CA2 (0.52) | CA2GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL7902271 | 0.98 | CA2 (0.52) | CA2GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL7902957 | 0.98 | CA2 (0.52) | CA2GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL13025496 | 0.93 | CA2 (0.50) | CA2GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL7036481 | 0.86 | CA2 (0.56) | CA2GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL4301825 | 0.85 | CA2 (0.57) | CA2GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL9727189 | 0.84 | CA2 (0.59) | CA2GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL1038699 | 0.84 | CA2 (0.59) | CA2GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL1259905 | 0.84 | CA2 (0.59) | CA2GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL9639022 | 0.84 | CA2 (0.59) | CA2GRIK1GRIK2SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309742-B2 | Use of the PigD protein for catalyzing 1,4-additions of 2-oxoalkanoates to α, β-unsaturated ketones | ALBERT-LUDWIGS-UNIVERSITAT FREIBURG (DE) | 2012-11-13 | — | — | US | disclosed |
| US-8309742-B2 | Use of the PigD protein for catalyzing 1,4-additions of 2-oxoalkanoates to α, β-unsaturated ketones | ALBERT-LUDWIGS-UNIVERSITAT FREIBURG (DE) | 2012-11-13 | — | — | US | disclosed |
| US-20100305337-A1 | Use Of The PIGD Protein For Catalyzing 1,4-Additions Of 2-Oxoalkanoates To Alpha, Beta-Unsaturated Ketones | ALBERT-LUDWIGS-UNIVERSITAT FREIBURG (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305337-A1 | Use Of The PIGD Protein For Catalyzing 1,4-Additions Of 2-Oxoalkanoates To Alpha, Beta-Unsaturated Ketones | ALBERT-LUDWIGS-UNIVERSITAT FREIBURG (DE) | 2010-12-02 | — | — | US | disclosed |
| EP-2142657-B1 | USE OF THE PIGD PROTEIN FOR CATALYZING 1,4-ADDITIONS OF 2-OXOALKANOATES TO ALPHA, BETA-UNSATURATED KETONES | UNIV ALBERT LUDWIGS FREIBURG (DE) | 2010-09-01 | — | — | EP | disclosed |
| EP-2142657-B1 | USE OF THE PIGD PROTEIN FOR CATALYZING 1,4-ADDITIONS OF 2-OXOALKANOATES TO ALPHA, BETA-UNSATURATED KETONES | UNIV ALBERT LUDWIGS FREIBURG (DE) | 2010-09-01 | — | — | EP | disclosed |
| EP-2142657-A1 | USE OF THE PIGD PROTEIN FOR CATALYZING 1,4-ADDITIONS OF 2-OXOALKANOATES TO ALPHA, BETA-UNSATURATED KETONES | Albert-Ludwigs-Universität Freiburg (DE) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008138450-A1 | USE OF THE PIGD PROTEIN FOR CATALYZING 1,4-ADDITIONS OF 2-OXOALKANOATES TO ALPHA, BETA-UNSATURATED KETONES | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305337-A1 | Use Of The PIGD Protein For Catalyzing 1,4-Additions Of 2-Oxoalkanoates To Alpha, Beta-Unsaturated Ketones | PGD, PC, PDK4 | CA2 975/4885GRIK1 913/4885GRIK2 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.